PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond

被引：261

作者：

Fattahi, Sadegh ^{[1
,2
,3
]}

Amjadi-Moheb, Fatemeh ^{[4
]}

Tabaripour, Reza ^{[5
]}

Ashrafi, Gholam Hossein ^{[6
]}

Akhavan-Niaki, Haleh ^{[4
]}

机构：

[1] Babol Univ Med Sci, Student Res Comm, Babol, Iran

[2] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran

[3] Pasteur Inst, North Res Ctr, Amol, Iran

[4] Babol Univ Med Sci, Dept Genet, Fac Med, Babol, Iran

[5] Islamic Azad Univ, Dept Cellular & Mol Biol, Babol Branch, Babol, Iran

[6] Kingston Univ London, Sch Life Sci Pharm & Chem, SEC Fac, Canc Theme, London KT12EE, England

来源：

LIFE SCIENCES | 2020年 / 262卷

关键词：

PI3K/AKT/mTOR pathway; Epigenetic modulation; Gastric cancer; Chemoresistance; Non-coding RNAs; Targeted therapy; PROMOTES CISPLATIN RESISTANCE; INHIBITS CELL-PROLIFERATION; ABERRANT DNA METHYLATION; HUMAN OVARIAN-CANCER; NF-KAPPA-B; AKT INHIBITOR; UP-REGULATION; PHOSPHOINOSITIDE; 3-KINASES; MESENCHYMAL TRANSITION; SCAFFOLDING FUNCTION;

D O I：

10.1016/j.lfs.2020.118513

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

PI3K/AKT/mTOR pathway is one of the most important signaling pathways involved in normal cellular processes. Its aberrant activation modulates autophagy, epithelial-mesenchymal transition, apoptosis, chemoresistance, and metastasis in many human cancers. Emerging evidence demonstrates that some infections as well as epigenetic regulatory mechanisms can control PI3K/AKT/mTOR signaling pathway. In this review, we focused on the role of this pathway in gastric cancer development, prognosis, and metastasis, with an emphasis on epigenetic alterations including DNA methylation, histone modifications, and post-transcriptional modulations through non-coding RNAs fluctuations as well as H. pylori and Epstein-Barr virus infections. Finally, we reviewed different molecular targets and therapeutic agents in clinical trials as a potential strategy for gastric cancer treatment through the PI3K/AKT/mTOR pathway.

引用

页数：16

共 50 条

[21] Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer
Tufail, Muhammad
Wan, Wen-Dong
Jiang, Canhua
Li, Ning
CHEMICO-BIOLOGICAL INTERACTIONS, 2024, 396
[22] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, Antonino
Foo, Aaron S. C.
Lam, Hiu Y.
Yap, Kenneth C. H.
Jacot, William
Jones, Robert H.
Eng, Huiyan
Nair, Madhumathy G.
Makvandi, Pooyan
Geoerger, Birgit
Kulke, Matthew H.
Baird, Richard D.
Prabhu, Jyothi S.
Carbone, Daniela
Pecoraro, Camilla
Teh, Daniel B. L.
Sethi, Gautam
Cavalieri, Vincenzo
Lin, Kevin H.
Javidi-Sharifi, Nathalie R.
Toska, Eneda
Davids, Matthew S.
Brown, Jennifer R.
Diana, Patrizia
Stebbing, Justin
Fruman, David A.
Kumar, Alan P.
MOLECULAR CANCER, 2023, 22 (01)
[23] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
HaiXia Li
JianFang Zeng
Keng Shen
Archives of Gynecology and Obstetrics, 2014, 290 : 1067 - 1078
[24] Interactions of PI3K/Akt/mTOR and estrogen receptor signaling in breast cancer
Shrivastav, Anuraag
Murphy, Leigh
BREAST CANCER MANAGEMENT, 2012, 1 (03) : 235 - 249
[25] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, Ben
Dienstmann, Rodrigo
Tabernero, Josep
ONCOTARGET, 2010, 1 (07) : 530 - 543
[26] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Chen, Jiezhong
Zhao, Kong-Nan
Li, Rui
Shao, Renfu
Chen, Chen
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
[27] Targeting PI3K/mTOR signaling in cancer
Arcaro, Alexandre
FRONTIERS IN ONCOLOGY, 2014, 4
[28] Targeting PI3K/mTOR Signaling in Cancer
Emerling, Brooke M.
Akcakanat, Argun
CANCER RESEARCH, 2011, 71 (24) : 7351 - 7359
[29] PI3k/AKT signaling pathway: Erythropoiesis and beyond
Jafari, Mahjoobeh
Ghadami, Elham
Dadkhah, Tahereh
Akhavan-Niaki, Haleh
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (03) : 2373 - 2385
[30] Compartmentalized PI3K/Akt/mTOR Signaling in Living Cells
Zhang, Jin
FASEB JOURNAL, 2015, 29

← 1 2 3 4 5 →